Quinacrine treatment trial for sporadic creutzfeldt-Jakob disease

Neurology

Volumn 81, Issue 23, 2013, Pages 2015-2023

  Geschwind, Michael D ^a   Kuo, Amy L ^a   Wong, Katherine S ^a   Haman, Aissa ^a   Devereux, Gillian ^a   Raudabaugh, Benjamin J ^a   Johnson, David Y ^a   Torres Chae, Charles C ^a   Finley, Ron ^a,b   Garcia, Paul ^a   Thai, Julie N ^a   Cheng, Hugo Q ^a   Neuhaus, John M ^b   Forner, Sven A ^a   Duncan, Jacque L ^a   Possin, Katherine L ^a   Dearmond, Stephen J ^b   Prusiner, Stanley B ^a,b   Miller, Bruce L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEPACRINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SECONDARY ANALYSIS; SPORADIC CREUTZFELDT JAKOB DISEASE; SURVIVAL; TELEPHONE INTERVIEW; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CREUTZFELDT-JAKOB SYNDROME; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; QUINACRINE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84892418749     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a9f3b4     Document Type: Article

References (36)

1. Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006;63:497-501
2. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62:714-718
3. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacoptherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-9841
4. Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74:4894-4897
5. Engel GL. Quinacrine effects on the central nervous system. JAMA 1966;197:505
6. Gaskill HS, Fitz-Hugh T. Toxic psychosis following Atabrine. Bull US Army Med Dept 1945;86:63-69
7. Wallace D. Antimalarial therapies. In:Wallace D, Hahn BH, editors. Dubois' Lupus Erythematosus, 5th ed. Baltimore: Williams & Wilkins; 1997:1117-1139
8. Evans RL, Khalid S, Kinney JL. Antimalarial psychosis revisited. Arch Dermatol 1984;120:765-767
9. Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004;17:158-163
10. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 1989;42:703-709
11. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607
12. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules [see comments]. Neurology 1993;43:2412-2414
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314
14. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
15. Stata Statistical Software [computer program]. Version release 11.1. College Station, TX: Stata Corporation; 2010
16. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-694
17. Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-1194
18. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334- 344
19. Haik S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004;63:2413-2415
20. Geschwind MD. Clinical trials for prion disease: difficult challenges, but hope for the future. Lancet Neurol 2009;8: 304-306
21. Gayrard V, Picard-Hagen N, Viguie C, Laroute V, Andreoletti O, Toutain PL. A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in an ovine model of scrapie. Br J Pharmacol 2005;144:386-393
22. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002;52:503-506
23. Ghaemmaghami S, Ahn M, Lessard P, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009;5:e1000673
24. May BC, Fafarman AT, Hong SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci USA 2003;100:3416-3421
25. Rollo IM. Drugs used in the chemotherapy of malaria. In: Goodman LS, Gilman A, editors. The Pharmacological Basis of Therapeutics, 4th ed. London: Macmillan Company; 1970:1095-1124
26. Van Dyke K, Lantz C, Szustkiewicz C. Quinacrine: mechanisms of antimalarial action. Science 1970;169:492-493
27. Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77:8462-8469
28. Ryou C, Legname G, Peretz D, Craig JC, Baldwin MA, Prusiner SB. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 2003; 83:837-843
29. Huang Y, Okochi H, May BC, et al. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos 2006;34:1136-1144
30. Satoh K, Shirabe S, Eguchi K, et al. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. Cell Mol Neurobiol 2004;24:873-875
31. Ghaemmaghami S, Watts JC, Nguyen HO, Hayashi S, DeArmond SJ, Prusiner SB. Conformational transformation and selection of synthetic prion strains. J Mol Biol 2011;413:527-542
32. Villa V, Tonelli M, Thellung S, et al. Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity. Neurotox Res 2011; 19:556-574
33. Yung L, Huang Y, Lessard P, et al. Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis 2004;4:53
34. Vogtherr M, Grimme S, Elshorst B, et al. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 2003;46:3563-3564
35. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. Darwinian evolution of prions in cell culture. Science 2010; 327:869-872
36. Wallace D. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-263